M&A Deal Summary

Cephalon Acquires Gemin X Biotechnologies

On March 22, 2011, Cephalon acquired life science company Gemin X Biotechnologies from Nexus Life Science Partners for 225M USD

Acquisition Highlights
  • This is Cephalon’s 6th transaction in the Life Science sector.
  • This is Cephalon’s 4th largest (disclosed) transaction.
  • This is Cephalon’s 1st transaction in Canada.
  • This is Cephalon’s 1st transaction in Quebec.

M&A Deal Summary
Date 2011-03-22
Target Gemin X Biotechnologies
Sector Life Science
Buyer(s) Cephalon
Sellers(s) Nexus Life Science Partners
Deal Type Add-on Acquisition
Deal Value 225M USD
Advisor(s) Citigroup Investment Banking (Financial)
Cooley (Legal)

Target

Gemin X Biotechnologies

Montreal, Quebec, Canada
Gemin X Biotechnologies Inc. is a biopharmaceutical company that engages in the discovery and development of small molecule cancer therapeutics based on the regulation of apoptosis. The company develops small molecules that target pathways for cancer, including regulators in the genesis and progression of cancer.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cephalon

Frazer, Pennsylvania, United States
Category Company
Founded 1987
Sector Life Science
Employees3,726
DESCRIPTION

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.

DEAL STATS #
Overall 6 of 7
Sector (Life Science) 6 of 7
Type (Add-on Acquisition) 5 of 6
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2011) 1 of 2
Size (of disclosed) 4 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-04-09 Mepha Pharma Ag

Aesch, Switzerland

Mepha is a pharmaceutical company developing, manufacturing and marketing branded and non-branded generic products in more than 50 countries. Mepha's R & D organization has developed improved branded generics either through new formulations or using drug delivery technologies, providing additional benefits for healthcare professionals and patients.

Buy $615M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-03-28 ChemGenex Pharmaceuticals

Menlo Park, California, United States

ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing personalized therapeutics in the areas of oncology, diabetes and obesity. ChemGenex’s lead compound, Ceflatonin®, is currently in Phase 2/3 clinical trials for chronic myeloid leukemia and Quinamed® is in Phase 2 clinical trials for several solid cancers. ChemGenex's pipeline also includes several pre-clinical stage anti-diabetes lead mole.

Buy $231M

Seller(S) 1

SELLER

Nexus Life Science Partners

New York, New York, United States
Category Growth Capital Firm
Founded 2001
Size Small
Type Sector Focused
DESCRIPTION

Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.

DEAL STATS #
Overall 15 of 22
Sector (Life Science) 14 of 18
Type (Add-on Acquisition) 6 of 10
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2011) 1 of 4
Size (of disclosed) 8 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-07-19 Dov Pharmaceutical

Somerset, New Jersey, United States

Dov Pharmaceutical (DOVP) focuses on novel drug candidates for central nervous system and other disorders, including cardiovascular and urological, that involve alterations in neuronal processing. Insomnia, pain and anxiolytic products have demonstrated efficacy in clinical trials. Other product candidates address the treatment of depression, angina and hypertension.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-05-16 Orthovita

Malvern, Pennsylvania, United States

Orthovita is a unique spine/orthopedic surgical biomaterials company offering advanced bone regeneration and soft tissue healing technologies. Their experience lies in developing and distributing novel, high-tech, synthetic-based biomaterial products. Orthovita currently has four key commercial product platforms: Vitoss Bone Graft Substitute, Vitagel Surgical Hemostat, Cortoss Synthetic Cortical Bone, and Imbibe Delivery and Disposable Systems.

Sell $316M
Mergr

Product

Company

Legal